MX389014B - Formas cristalinas de un compuesto inhibidor de jak - Google Patents

Formas cristalinas de un compuesto inhibidor de jak

Info

Publication number
MX389014B
MX389014B MX2019012945A MX2019012945A MX389014B MX 389014 B MX389014 B MX 389014B MX 2019012945 A MX2019012945 A MX 2019012945A MX 2019012945 A MX2019012945 A MX 2019012945A MX 389014 B MX389014 B MX 389014B
Authority
MX
Mexico
Prior art keywords
crystalline forms
crystalline
inhibiting compound
hydrates
oxalate
Prior art date
Application number
MX2019012945A
Other languages
English (en)
Spanish (es)
Other versions
MX2019012945A (es
Inventor
Glenn D Crater
Jerry Nzerem
Marta Dabros
Melanie A Kleinschek
Venkat R Thalladi
Original Assignee
Theravance Biopharma R&D Ip Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Theravance Biopharma R&D Ip Llc filed Critical Theravance Biopharma R&D Ip Llc
Publication of MX2019012945A publication Critical patent/MX2019012945A/es
Publication of MX389014B publication Critical patent/MX389014B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4468—Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2019012945A 2017-05-01 2018-04-30 Formas cristalinas de un compuesto inhibidor de jak MX389014B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762492571P 2017-05-01 2017-05-01
PCT/US2018/030144 WO2018204236A1 (en) 2017-05-01 2018-04-30 Crystalline forms of a jak inhibitor compound

Publications (2)

Publication Number Publication Date
MX2019012945A MX2019012945A (es) 2019-12-16
MX389014B true MX389014B (es) 2025-03-20

Family

ID=62165729

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019012945A MX389014B (es) 2017-05-01 2018-04-30 Formas cristalinas de un compuesto inhibidor de jak

Country Status (13)

Country Link
US (1) US10251874B2 (https=)
EP (1) EP3619208B1 (https=)
JP (1) JP7096268B2 (https=)
KR (1) KR20200003121A (https=)
CN (1) CN110603255B (https=)
AU (1) AU2018261591B2 (https=)
CA (1) CA3059790A1 (https=)
MX (1) MX389014B (https=)
MY (1) MY200348A (https=)
PH (1) PH12019502425A1 (https=)
SG (1) SG11201909376TA (https=)
TW (1) TWI808083B (https=)
WO (1) WO2018204236A1 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA123633C2 (uk) 2015-11-03 2021-05-05 Тереванс Байофарма Ар Енд Ді Айпі, Елелсі Сполуки інгібітору jak-кінази для лікування респіраторного захворювання
WO2018165392A1 (en) 2017-03-09 2018-09-13 Theravance Biopharma R&D Ip, Llc Jak inhibitors containing a 4-membered heterocyclic amide
AR111495A1 (es) 2017-05-01 2019-07-17 Theravance Biopharma R&D Ip Llc Compuestos de imidazo-piperidina fusionada como inhibidores de jak
WO2018204233A1 (en) 2017-05-01 2018-11-08 Theravance Biopharma R&D Ip, Llc Methods of treatment using a jak inhibitor compound
JP2021535176A (ja) 2018-09-04 2021-12-16 セラヴァンス バイオファーマ アール＆ディー アイピー， エルエルシー Ｊａｋ阻害剤およびその中間体を調製するためのプロセス
FI3837258T3 (fi) 2018-09-04 2024-05-27 Theravance Biopharma R&D Ip Llc Dimetyyliaminoatsetidiiniamideja jak-estäjinä
UA127328C2 (uk) 2018-09-04 2023-07-19 Тереванс Байофарма Ар Енд Ді Айпі, Елелсі 5-7-членні гетероциклічні аміди як інгібітори jak
KR20210084512A (ko) 2018-10-29 2021-07-07 세라밴스 바이오파마 알앤디 아이피, 엘엘씨 Jak 억제제로서 2-아자비시클로 헥산 화합물
TW202144343A (zh) * 2020-03-02 2021-12-01 美商施萬生物製藥研發 Ip有限責任公司 Jak抑制劑化合物之結晶水合物
WO2022204473A1 (en) * 2021-03-26 2022-09-29 Theravance Biopharma R&D Ip, Llc Crystalline form of a dihydrochloride salt of a jak inhibitor compound
EP4359402B1 (en) 2021-06-25 2026-03-11 Theravance Biopharma R&D IP, LLC Imidazolo indazole compounds as jak inhibitors
KR20230092805A (ko) * 2021-12-17 2023-06-26 주식회사 대웅제약 (2R, 3S)-2-(3-(4,5-디클로로-1H-벤조[d]이미다졸-1-일)프로필)피페리딘-3-올의 신규한 산부가염 및 결정형

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI262914B (en) 1999-07-02 2006-10-01 Agouron Pharma Compounds and pharmaceutical compositions for inhibiting protein kinases
EP1648455A4 (en) 2003-07-23 2009-03-04 Exelixis Inc MODULATORS OF ALK PROTEIN (ANAPLASTIC LYMPHOMA KINASE) AND METHODS OF USE
US20050090529A1 (en) 2003-07-31 2005-04-28 Pfizer Inc 3,5 Disubstituted indazole compounds with nitrogen-bearing 5-membered heterocycles, pharmaceutical compositions, and methods for mediating or inhibiting cell proliferation
US7884109B2 (en) 2005-04-05 2011-02-08 Wyeth Llc Purine and imidazopyridine derivatives for immunosuppression
US8648069B2 (en) 2007-06-08 2014-02-11 Abbvie Inc. 5-substituted indazoles as kinase inhibitors
JP2010111624A (ja) 2008-11-06 2010-05-20 Shionogi & Co Ltd Ｔｔｋ阻害作用を有するインダゾール誘導体
WO2010114971A1 (en) 2009-04-03 2010-10-07 Sepracor Inc. Compounds for treating disorders mediated by metabotropic glutamate receptor 5, and methods of use thereof
LT3001903T (lt) 2009-12-21 2018-01-10 Samumed, Llc 1h-pirazolo[3,4-b]piridinai ir jų terapinis panaudojimas
US8575336B2 (en) * 2011-07-27 2013-11-05 Pfizer Limited Indazoles
SI3077395T1 (en) 2013-12-05 2018-03-30 Pfizer Inc. Pyrrolo(2,3-d)pyrimidinyl, pyrrolo(2,3-b)pyrazinyl and pyrrolo(2,3-d)pyridinyl acrylamides
KR20170002623A (ko) 2014-05-14 2017-01-06 화이자 인코포레이티드 피라졸로피리딘 및 피라졸로피리미딘
WO2016026078A1 (en) 2014-08-19 2016-02-25 Changzhou Jiekai Pharmatech Co., Ltd. Heterocyclic compounds as erk inhibitors
KR101663277B1 (ko) 2015-03-30 2016-10-06 주식회사 녹십자 TNIK, IKKε 및 TBK1 억제제로서의 피라졸계 유도체 및 이를 포함하는 약학적 조성물
DK3371185T3 (da) 2015-11-03 2020-11-30 Topivert Pharma Ltd 4,5,6,7-tetrahydro-1h-imidazo[4,5-c]pyridin og 1,4,5,6,7,8-hexahydroimidazo[4,5-d]azepinderivater som janus-kinase-inhibitorer
UA123633C2 (uk) * 2015-11-03 2021-05-05 Тереванс Байофарма Ар Енд Ді Айпі, Елелсі Сполуки інгібітору jak-кінази для лікування респіраторного захворювання
WO2017077283A1 (en) 2015-11-03 2017-05-11 Topivert Pharma Limited 4,5,6,7-tetrahydro-1h-imidazo[4,5-c]pyridine and 1,4,5,6,7,8-hexahydroimidazo[4,5-d]azepine derivatives as janus kinase inhibitors

Also Published As

Publication number Publication date
AU2018261591B2 (en) 2021-09-02
TWI808083B (zh) 2023-07-11
RU2019138700A (ru) 2021-06-02
JP2020518582A (ja) 2020-06-25
WO2018204236A1 (en) 2018-11-08
KR20200003121A (ko) 2020-01-08
MY200348A (en) 2023-12-21
MX2019012945A (es) 2019-12-16
SG11201909376TA (en) 2019-11-28
TW201900643A (zh) 2019-01-01
JP7096268B2 (ja) 2022-07-05
US20180311223A1 (en) 2018-11-01
EP3619208A1 (en) 2020-03-11
RU2019138700A3 (https=) 2022-01-26
CN110603255A (zh) 2019-12-20
EP3619208B1 (en) 2023-06-07
CA3059790A1 (en) 2018-11-08
EP3619208C0 (en) 2023-06-07
CN110603255B (zh) 2023-02-10
US10251874B2 (en) 2019-04-09
AU2018261591A1 (en) 2019-11-07
PH12019502425A1 (en) 2020-06-29

Similar Documents

Publication Publication Date Title
MX389014B (es) Formas cristalinas de un compuesto inhibidor de jak
BR112018008966A2 (pt) compostos inibidores de jak quinase para o tratamento de doença respiratória
MX2018015625A (es) Compuestos y composiciones para inhibir la actividad de shp2.
CU20160188A7 (es) Compuestos de indazole substituidos como inhibidores de irak4
DOP2016000281A (es) Compuestos de imidazo[4,5-c]quinolin-2-ona y su uso para tratar cáncer
CL2020000610A1 (es) Compuestos de bisamida que activan el sarcómero y sus usos.
MX2020001757A (es) Compuestos, sales de los mismos y metodos para el tratamiento de enfermedades.
TN2016000268A1 (en) N-azaspirocycloalkane substituted n-heteroaryl compounds and compositions for inhibiting the activity of shp2.
EA201792116A1 (ru) Ингибитор янус-киназы
MX2015009950A (es) Compuestos de imidazopiridina y sus usos.
BR112017013440A2 (pt) compostos de isoquinolina para o tratamento de hiv
EA201992128A1 (ru) Конденсированные имидазопиперидиновые ингибиторы jak
UA118149C2 (uk) Інгібітор jak
BR112017003054A2 (pt) compostos de aminopirimidinila como inibidores de jak
AR096543A1 (es) INHIBIDORES DE QUINASA PI3 d Y g SELECTIVOS DUALES
TN2017000075A1 (en) Compounds and compositions as raf kinase inhibitors
EA201990833A1 (ru) Соединение пиридина
EA201692249A1 (ru) Ингибиторы фосфатидилинозитол-3-киназы
DOP2019000193A (es) Nuevo compuesto heterocíclico, su método de preparación y composición farmacéutica que lo comprende
EA201692266A1 (ru) Ингибиторы фосфатидилинозитол-3-киназы
MX2020003593A (es) Compuestos de benzotiazol y metodos para usar los mismos para tratar trastornos neurodegenerativos.
DOP2016000308A (es) Compuestos de 1, 3, 4-tiadiazol y uso de los mismos para el tratamiento del cáncer
CO2019001181A2 (es) Compuestos de heteroarilcarboxamida como inhibidores de ripk2
CO2019004978A2 (es) Compuestos terapéuticos y métodos para utilizarlos
UY36875A (es) Composiciones inhibidoras de bromodominios para el tratamiento de diversas enfermedades